Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells

Fig. 4

Effect of Amatuximab and gemcitabine combination treatment in human pancreatic cancer cell lines. AsPC-1, Capan-2, Panc-1 and MIA Paca-2 cells were treated with gemcitabine (1 μM) and/or Amatuximab (100 μg/mL) for 48 h. Viable cells were stained with trypan blue and counted

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us